Study shows diabetes drug promising

	Tweet

Denmark’s Novo Nordisk, the world’s biggest maker of insulin, said on Friday a phase II study showed promising results for its diabetes drug liraglutide.

“The impressive clinical data for liraglutide holds great promise for improving the treatment of type 2 diabetes; simultaneous glucose control and weight loss in the absence of hypoglycaemic events,” Novo Nordisk chief science officer Mads Krogsgaard Thomsen said in a statement.

NovoNordisk said phase III studies with liraglutide would begin in February 2006. 

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]